Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma

American Journal of Surgical Pathology

Volumn 37, Issue 9, 2013, Pages 1342-1348

  Mao, Tsui Lien ^a   Ardighieri, Laura ^b   Ayhan, Ayse ^c   Kuo, Kuan Ting ^a   Wu, Chen Hsuan ^b   Wang, Tian Li ^b   Shih, Ie Ming ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

Author keywords

ARID1A; Endometrioid carcinoma; Gynecology pathology

Indexed keywords

ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; DISEASE COURSE; DOWN REGULATION; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; TIME; UTERUS CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 84884507473     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182889dc3     Document Type: Article

References (26)

1. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625-632.
2. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-231.
3. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363:1532-1543.
4. Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 2011;43:828-829.
5. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539-542.
6. Medina PP, Romero OA, Kohno T, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat. 2008;29:617-622.
7. Rodriguez-Nieto S, Canada A, Pros E, et al. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum Mutat. 2011;32:E1999-E2017.
8. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33:100-103.
9. Mamo A, Cavallone L, Tuzmen S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 2012;31:2090-2100.
10. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43:1219-1223.
11. Liang H, Cheung LW, Li J, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22: 2120-2129.
12. Maeda D, Shih IeM. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol. 2013;20:45-52.
13. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224:328-333.
14. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients. Cancer. 1985;56:403-412.
15. Guan B, Wang TL, Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71:6718-6727.
16. Tanaka M, Kyo S, Kayaya T, et al. Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium. Am J Pathol. 2003;163:295-301.
17. Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 2001;61:4311-4314.
18. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22:1310-1315.
19. Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol. 2009;62:777-785.
20. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32: 569-577.
21. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int. 2010;2010:162363.
22. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30.
23. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
24. Zannoni GF, Vellone VG, Arena V, et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch. 2010;457:27-34.
25. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 2012;460:77-87.
26. Yamamoto S, Tsuda H, Takano M, et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012;25:615-624.